ATLAS mPBPK: A MATLAB‐Based Tool for Modeling and Simulation of Minimal Physiologically‐Based Pharmacokinetic Models
暂无分享,去创建一个
William J Jusko | Panteleimon D Mavroudis | Vivaswath S Ayyar | W. Jusko | Vivaswath S. Ayyar | P. D. Mavroudis
[1] F. Magrini,et al. Extended Report , 2011 .
[2] Sebastian Schneckener,et al. Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits , 2018, PloS one.
[3] K Rowland-Yeo,et al. Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development , 2013, CPT: pharmacometrics & systems pharmacology.
[4] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[5] William J. Jusko,et al. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model , 2015, Pharmaceutical Research.
[6] D. DuBois,et al. Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models , 2017, Drug Metabolism and Disposition.
[7] Malcolm Rowland,et al. Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[8] A. Kamath,et al. Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model , 2018, mAbs.
[9] H. Wiig,et al. Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle. , 2001, American journal of physiology. Heart and circulatory physiology.
[10] J E Simmons,et al. Applications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in rats. , 1994, Toxicology and applied pharmacology.
[11] M Rowland,et al. Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions , 2012, Clinical pharmacology and therapeutics.
[12] E. Laemmel,et al. Towards a better understanding of lymph circulation , 2008 .
[13] Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in Arthritic Rats , 2018, Pharmaceutical Research.
[14] W. Jusko,et al. Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis , 2016, Journal of Pharmacokinetics and Pharmacodynamics.
[15] William J. Jusko,et al. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[16] William J. Jusko,et al. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[17] D. DuBois,et al. Characterization and Interspecies Scaling of rhTNF-α Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models , 2017, Drug Metabolism and Disposition.
[18] D. DuBois,et al. Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats , 2007, Biopharmaceutics & drug disposition.
[19] M. Roberts,et al. The effect of posture on the pharmacokinetics of intravenous benzylpenicillin , 2004, European Journal of Clinical Pharmacology.
[20] Ioannis P. Androulakis,et al. A framework for 2-stage global sensitivity analysis of GastroPlus™ compartmental models , 2018, Journal of Pharmacokinetics and Pharmacodynamics.
[21] Y. Sasaki,et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer , 1999, British Journal of Cancer.
[22] M. Roberts,et al. The effects of posture on the pharmacokinetics of intramuscular benzylpenicillin , 2004, European Journal of Clinical Pharmacology.
[23] D. DuBois,et al. Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis , 2017, Drug Metabolism and Disposition.
[24] Leon Aarons,et al. Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.
[25] M. De Carlo,et al. Interstitial exclusion of IgG in rat tissues estimated by continuous infusion. , 1994, The American journal of physiology.
[26] William J. Jusko,et al. Applications of minimal physiologically-based pharmacokinetic models , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[27] William J. Jusko,et al. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[28] Leonid Gibiansky,et al. Approximations of the target-mediated drug disposition model and identifiability of model parameters , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[29] D. DuBois,et al. Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen , 2017, Drug Metabolism and Disposition.
[30] William J Jusko,et al. Moving from basic toward systems pharmacodynamic models. , 2013, Journal of pharmaceutical sciences.
[31] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[32] Hemant Sarin,et al. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability , 2010, Journal of angiogenesis research.
[33] Kevin McNally,et al. A Workflow for Global Sensitivity Analysis of PBPK Models , 2011, Front. Pharmacol..